AC Immune S.A. (ACIU) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)

A side-by-side comparison of AC Immune S.A. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
AC Immune S.A. logo
ACIU
AC Immune S.A.
$257M
$2.53HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Lexeo Therapeutics, Inc. Common Stock logo
LXEO
Lexeo Therapeutics, Inc. Common Stock
$260M
$3.31HealthcareDelayed quote: Oct 6, 2026, 1:45 PM EDT

Total return — ACIU vs LXEO

growth of $100 · dividends reinvested · last 3y
ACIU -8.1% (-2.8%/yr)LXEO -66.1% (-30.3%/yr)ACIU compounded faster over this window
50100150200Start $100202420252026$92$34
ACIU LXEO

ACIU vs LXEO: by the numbers

  • •LXEO is the larger company ($260M vs $257M market cap).
  • •Both run net losses; LXEO's is the smaller (0.00% vs -249.94% net margin).

Metrics side by side

Valuation

MetricACIULXEO
P/S ratio11.86N/A
P/B ratio5.921.10

Profitability

MetricACIULXEO
Gross margin100.00%0.00%
Operating margin-1927.32%0.00%
Net margin-249.94%0.00%
ROE-124.67%-37.12%
ROIC-89.43%-39.76%

Growth (annualized)

MetricACIULXEO
Revenue CAGR (5Y)-23.70%N/A
Total return CAGR (5Y)-16.03%N/A

Go deeper

Full ACIU analysisFull LXEO analysisInteractive comparison tool

Dig into the metrics

AC Immune ROELexeo Therapeutics, Inc. Common Stock ROEAC Immune operating marginLexeo Therapeutics, Inc. Common Stock operating marginAC Immune revenue growthLexeo Therapeutics, Inc. Common Stock revenue growthAC Immune free cash flowLexeo Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.